Search - tctmd.com

Displaying 61 - 80 of 84

Sort: Relevancy | Date

EVERBIO II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting and Biolimus-Eluting Metallic Stents in Patients with Coronary Artery Disease

Presentation TCT 2014

EVERBIO II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting and Biolimus-Eluting Metallic Stents in Patients with Coronary Artery Disease

Presenter: Mitchell W. Krucoff, Giulio G. Stefanini, Stephane Cook

September 16, 2014

RIBS IV: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents

Presentation TCT 2014

RIBS IV: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents

Presenter: Gregg W. Stone, Pieter C. Smits, Fernando Alfonso

September 14, 2014

ABSORB II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus an Everolimus-Eluting Metallic Stent in Patients with Coronary Artery Disease

Presentation TCT 2014

ABSORB II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus an Everolimus-Eluting Metallic Stent in Patients with Coronary Artery Disease

Presenter: Gregg W. Stone, Pieter C. Smits, Patrick W. Serruys

September 14, 2014

News Conference News TCT 2014

COMPARE II: BES, EES Show Similar Outcomes at Three Years

September 13, 2014

News Conference News EuroPCR 2014

CENTURY II: Bioresorbable Polymer DES Stands up to Everolimus-Eluting Device

May 20, 2014

News Daily News

Drug-Eluting Balloons Reduce Restenosis, TLR in Diabetic Patients with CLI

Yael L. Maxwell

February 26, 2014

DUTCH PEERS (TWENTE II): A Prospective, Randomized, "All-Comers" Trial of Third-Generation Zotarolimus-Eluting Stents vs. Everolimus-Eluting Coronary Stents

Presentation TCT 2013

DUTCH PEERS (TWENTE II): A Prospective, Randomized, "All-Comers" Trial of Third-Generation Zotarolimus-Eluting Stents vs. Everolimus-Eluting Coronary Stents

Presenter: Clemens von Birgelen

October 31, 2013

News Daily News

ESC Consensus Statement Outlines Proper Role of Platelet Function Testing After PCI

September 30, 2013

News Daily News

SPIRIT Meta-analysis Confirms Overall Superiority of Xience over Taxus

September 20, 2013

News Daily News

Meta-análisis de SPIRIT confirma superioridad total de Xience sobre Taxus

September 20, 2013

News Conference News EuroPCR 2013

EuroPCR 2013: From Cutting-Edge Devices to the Clinical Challenges

May 29, 2013

News Daily News

BIOSOLVE-1 Shows Improvement in Paclitaxel-Eluting Bioabsorbable Stent

March 25, 2013

News Daily News

BIOSOLVE-1 Confirma la Mejora en los Stents Bioabsorbibles liberadores de Paclitaxel

March 25, 2013

DESSOLVE II: A Prospective, Randomized Trial of a Biodegradable Polymer-based Sirolimus-Eluting Stent vs a Zotarolimus-Eluting Stent (Micell)

Presentation TCT 2012

DESSOLVE II: A Prospective, Randomized Trial of a Biodegradable Polymer-based Sirolimus-Eluting Stent vs a Zotarolimus-Eluting Stent (Micell)

Presenter: David Kandzari

October 23, 2012

News Daily News

Los Balones liberadores de Fármacos arrojan Resultados Positivos en el Tratamiento de la Reestenosis intra stent

October 05, 2012

News Daily News

Drug-eluting Balloons Show Positive Results in Treating In-stent Restenosis

October 05, 2012

News Conference News EuroPCR 2012

Biolimus-Eluting Stents Perform Well in STEMI, Unselected Populations

May 15, 2012

News Conference News ACC 2012

RESOLUTE: Zotarolimus-Eluting Stent Fares Well at 2 Years

March 26, 2012

News Daily News

Experts Give Their Picks for Most Important Developments of 2011

March 08, 2012

News Daily News

NEXT Up: Polymer-Free SES Angiographically Superior to Taxus

January 24, 2012

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.